| Control | Tomotherapy | P-value 1 sided | ||||
---|---|---|---|---|---|---|---|
 | Number of patients evaluated | Observed grade ≥1 | % grade ≥1 | Number of patients evaluated | Observed grade ≥1 | % grade ≥1 |  |
Skin | Â | Â | Â | Â | Â | Â | Â |
at 2 months | 32 | 65.6 | 21 | 36 | 24 | 66.7 | 0.636 |
at 1 year | 31 | 14 | 45.2 | 36 | 14 | 38.9 | 0.393 |
at 2 years | 20 | 12 | 60.0 | 20 | 6 | 30.0 | 0.056 |
Breast/chest wall fibrosis | |||||||
at 1 year | 32 | 12 | 37.5 | 36 | 10 | 27.8 | 0.276 |
at 2 years | 24 | 9 | 37.5 | 24 | 6 | 25.0 | 0.267 |
Arm lymphedema | |||||||
at 2 months | 32 | 2 | 6.2 | 36 | 1 | 2.8 | 0.455 |
at 1 year | 32 | 2 | 6.2 | 36 | 2 | 5.6 | 0.647 |
at 2 years | 24 | 3 | 12.5 | 24 | 3 | 12.5 | 0.667 |
Heart function | |||||||
at 2 months | 32 | 9 | 28.1 | 35 | 4 | 11.4 | 0.078 |
at 1 year | 31 | 4 | 12.9 | 36 | 8 | 22.2 | 0.906 |
at 2 years | 21 | 1 | 4.8 | 22 | 1 | 4.6 | 0.744 |
Lung toxicity score based on change in FEV1 (*) | |||||||
at 2 months | 30 | 4 | 13.3 | 34 | 3 | 8.8 | 0.429 |
at 1 year | 29 | 4 | 13.8 | 34 | 4 | 11.8 | 0.552 |
at 2 years | 24 | 5 | 20.8 | 27 | 4 | 14.8 | 0.422 |
Lung toxicity score based on change in DLco (*) | |||||||
at 2 months | 30 | 10 | 33.3 | 34 | 8 | 23.5 | 0.277 |
at 1 year | 29 | 8 | 27.6 | 34 | 3 | 8.8 | 0.052 |
at 2 years | 24 | 7 | 29.2 | 27 | 2 | 7.4 | 0.047 |
Lung toxicity based on change in FEV1 and DLco (*) | |||||||
at 2 months | 30 | 12 | 40.0 | 34 | 10 | 34.3 | 0.266 |
at 1 year | 29 | 12 | 41.4 | 34 | 6 | 28.6 | 0.036 |
at 2 years | 24 | 10 | 41.7 | 27 | 5 | 22.2 | 0.066 |